Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6521595 | 0.93 | CHRM3 (0.41) | CHRM2CHRM3ADRB2DRD2DRD1 | |
| SCHEMBL12789312 | 0.92 | CHRM3 (0.43) | CHRM2CHRM3ADRB2DRD2DRD1 | |
| Trifluoroacetic Acid SCHEMBL6522142 | 0.85 | CHRM3 (0.41) | CHRM2CHRM3ADRB2DRD2DRD1 | |
| Trifluoroacetic Acid SCHEMBL6523373 | 0.84 | CHRM2 (0.42) | CHRM2CHRM3ADRB2DRD2DRD1 | |
| SCHEMBL12846730 | 0.84 | CHRM3 (0.44) | CHRM2CHRM3ADRB2DRD2DRD1 | |
| SCHEMBL1245050 | 0.83 | CHRM2 (0.44) | CHRM2CHRM3ADRB2DRD2DRD1 | |
| SCHEMBL6523329 | 0.83 | CHRM3 (0.41) | CHRM2CHRM3ADRB2 | |
| Sulfuric Acid SCHEMBL1246196 | 0.82 | CHRM2 (0.44) | CHRM2CHRM3ADRB2DRD2DRD1 | |
| Trifluoroacetic Acid SCHEMBL6527403 | 0.82 | CHRM3 (0.44) | CHRM2CHRM3ADRB2DRD2DRD1 | |
| Trifluoroacetic Acid SCHEMBL6523286 | 0.81 | CHRM3 (0.46) | CHRM2CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | CHRM2 157/4885CHRM3 97/4885ADRB2 2/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | CHRM2 157/4885CHRM3 97/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.